Javid Moslehi
Last active: 2/24/2019


Dr. Moslehi is a physician-scientist with a background in myocyte biology and myocardial response to such stresses as hypoxia, aging, and chemotherapies. He is an Assistant Professor of Cardiovascular Medicine and Oncology and is the Director of the Cardio-Oncology Program at Vanderbilt.

Dr. Moslehi graduated from Johns Hopkins University and University of Connecticut School of Medicine. He completed internship and residency in internal medicine at Johns Hopkins Hospital followed by cardiovascular and vascular medicine fellowships at the Brigham and Women's Hospital and Harvard Medical School. He then completed a post-doctoral fellowship at the Dana-Farber Cancer Institute focusing on the role of angiogenesis in heart disease. In 2009, Dr. Moslehi joined the faculty at the Harvard Medical School and founded the Cardio-Oncology program at Brigham and Women’s Hospital and Dana-Farber Cancer Institute.

In 2014, he joined the faculty at Vanderbilt University School of Medicine where he is also the Director of the Cardio-Oncology Program. His interests in Cardio-Oncology include the cardiovascular health of cancer survivors as well as cardiotoxicities associated with novel targeted cancer therapies. His clinic is working to understand the mechanisms of toxicity associated with novel chemotherapies and is developing strategies to prevent and treat these complications. Dr. Moslehi’s primary focus in laboratory research is basic myocyte biology and myocardial adaptation to various stresses, including hypoxia, aging and chemotherapies.


The following timeline graph is generated from all co-authored publications.

Featured publications are shown below:

  1. Influenza vaccination and myocarditis among patients receiving immune checkpoint inhibitors. Awadalla M, Golden DLA, Mahmood SS, Alvi RM, Mercaldo ND, Hassan MZO, Banerji D, Rokicki A, Mulligan C, Murphy SPT, Jones-O'Connor M, Cohen JV, Heinzerling LM, Armanious M, Sullivan RJ, Damrongwatanasuk R, Chen CL, Gupta D, Kirchberger MC, Moslehi JJ, Shah SP, Ganatra S, Thavendiranathan P, Rizvi MA, Sahni G, Lyon AR, Tocchetti CG, Mercurio V, Thuny F, Ederhy S, Mahmoudi M, Lawrence DP, Groarke JD, Nohria A, Fradley MG, Reynolds KL, Neilan TG (2019) J Immunother Cancer 7(1): 53
    › Primary publication · 30795818 (PubMed) · PMC6387531 (PubMed Central)
  2. Cardio-Oncology: Vascular and Metabolic Perspectives: A Scientific Statement From the American Heart Association. Campia U, Moslehi JJ, Amiri-Kordestani L, Barac A, Beckman JA, Chism DD, Cohen P, Groarke JD, Herrmann J, Reilly CM, Weintraub NL (2019) Circulation 139(13): e579-e602
    › Primary publication · 30786722 (PubMed) · PMC6530491 (PubMed Central)
  3. The forgotten right ventricle in cardio-oncology. Jahangir E, Harinstein ME, Murthy VL, Moslehi J (2019) J Nucl Cardiol
    › Primary publication · 30771160 (PubMed) · PMC6697233 (PubMed Central)
  4. Cardiovascular toxicities associated with immune checkpoint inhibitors. Hu JR, Florido R, Lipson EJ, Naidoo J, Ardehali R, Tocchetti CG, Lyon AR, Padera RF, Johnson DB, Moslehi J (2019) Cardiovasc Res 115(5): 854-868
    › Primary publication · 30715219 (PubMed) · PMC6452314 (PubMed Central)
  5. Thrombotic microangiopathy as a cause of cardiovascular toxicity from the BCR-ABL1 tyrosine kinase inhibitor ponatinib. Latifi Y, Moccetti F, Wu M, Xie A, Packwood W, Qi Y, Ozawa K, Shentu W, Brown E, Shirai T, McCarty OJ, Ruggeri Z, Moslehi J, Chen J, Druker BJ, López JA, Lindner JR (2019) Blood 133(14): 1597-1606
    › Primary publication · 30692122 (PubMed) · PMC6450432 (PubMed Central)
  6. Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis. Brown JR, Moslehi J, Ewer MS, O'Brien SM, Ghia P, Cymbalista F, Shanafelt TD, Fraser G, Rule S, Coutre SE, Dilhuydy MS, Cramer P, Jaeger U, Dreyling M, Byrd JC, Treon S, Liu EY, Chang S, Bista A, Vempati R, Boornazian L, Valentino R, Reddy V, Mahler M, Yang H, Graef T, Burger JA (2019) Br J Haematol 184(4): 558-569
    › Primary publication · 30506764 (PubMed) · PMC6587776 (PubMed Central)
  7. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Salem JE, Manouchehri A, Moey M, Lebrun-Vignes B, Bastarache L, Pariente A, Gobert A, Spano JP, Balko JM, Bonaca MP, Roden DM, Johnson DB, Moslehi JJ (2018) Lancet Oncol 19(12): 1579-1589
    › Primary publication · 30442497 (PubMed) · PMC6287923 (PubMed Central)
  8. Immune Checkpoint Inhibitor-Associated Myositis. Anquetil C, Salem JE, Lebrun-Vignes B, Johnson DB, Mammen AL, Stenzel W, Léonard-Louis S, Benveniste O, Moslehi JJ, Allenbach Y (2018) Circulation 138(7): 743-745
    › Primary publication · 30359135 (PubMed)
  9. Survivorship, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. Denlinger CS, Sanft T, Baker KS, Broderick G, Demark-Wahnefried W, Friedman DL, Goldman M, Hudson M, Khakpour N, King A, Koura D, Lally RM, Langbaum TS, McDonough AL, Melisko M, Montoya JG, Mooney K, Moslehi JJ, O'Connor T, Overholser L, Paskett ED, Peppercorn J, Pirl W, Rodriguez MA, Ruddy KJ, Silverman P, Smith S, Syrjala KL, Tevaarwerk A, Urba SG, Wakabayashi MT, Zee P, McMillian NR, Freedman-Cass DA (2018) J Natl Compr Canc Netw 16(10): 1216-1247
    › Primary publication · 30323092 (PubMed) · PMC6438378 (PubMed Central)
  10. Increased Reporting of Immune Checkpoint Inhibitor-Associated Diabetes. Wright JJ, Salem JE, Johnson DB, Lebrun-Vignes B, Stamatouli A, Thomas JW, Herold KC, Moslehi J, Powers AC (2018) Diabetes Care 41(12): e150-e151
    › Primary publication · 30305348 (PubMed)
  11. Bid maintains mitochondrial cristae structure and function and protects against cardiac disease in an integrative genomics study. Salisbury-Ruf CT, Bertram CC, Vergeade A, Lark DS, Shi Q, Heberling ML, Fortune NL, Okoye GD, Jerome WG, Wells QS, Fessel J, Moslehi J, Chen H, Roberts LJ, Boutaud O, Gamazon ER, Zinkel SS (2018) Elife
    › Primary publication · 30281024 (PubMed) · PMC6234033 (PubMed Central)
  12. Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. Wang DY, Salem JE, Cohen JV, Chandra S, Menzer C, Ye F, Zhao S, Das S, Beckermann KE, Ha L, Rathmell WK, Ancell KK, Balko JM, Bowman C, Davis EJ, Chism DD, Horn L, Long GV, Carlino MS, Lebrun-Vignes B, Eroglu Z, Hassel JC, Menzies AM, Sosman JA, Sullivan RJ, Moslehi JJ, Johnson DB (2018) JAMA Oncol 4(12): 1721-1728
    › Primary publication · 30242316 (PubMed) · PMC6440712 (PubMed Central)
  13. Cardiac Toxicities in the Era of Precision Medicine: Underlying Risk Factors, Targeted Therapies, and Cardiac Biomarkers. Blaes AH, Thavendiranathan P, Moslehi J (2018) Am Soc Clin Oncol Educ Book : 764-774
    › Primary publication · 30231407 (PubMed)
  14. Immune checkpoint inhibitors and cardiovascular toxicity. Lyon AR, Yousaf N, Battisti NML, Moslehi J, Larkin J (2018) Lancet Oncol 19(9): e447-e458
    › Primary publication · 30191849 (PubMed)
  15. Reporting of immune checkpoint inhibitor-associated myocarditis - Authors' reply. Moslehi JJ, Salem JE, Sosman JA, Lebrun-Vignes B, Johnson DB (2018) Lancet 392(10145): 384-385
    › Primary publication · 30102170 (PubMed)
  16. Hypogonadism as a Reversible Cause of Torsades de Pointes in Men. Salem JE, Waintraub X, Courtillot C, Shaffer CM, Gandjbakhch E, Maupain C, Moslehi JJ, Badilini F, Haroche J, Gougis P, Fressart V, Glazer AM, Hidden-Lucet F, Touraine P, Lebrun-Vignes B, Roden DM, Bachelot A, Funck-Brentano C (2018) Circulation 138(1): 110-113
    › Primary publication · 29967236 (PubMed) · PMC6053686 (PubMed Central)
  17. Cardiovascular Disease in Survivors of Childhood Cancer: Insights Into Epidemiology, Pathophysiology, and Prevention. Armenian SH, Armstrong GT, Aune G, Chow EJ, Ehrhardt MJ, Ky B, Moslehi J, Mulrooney DA, Nathan PC, Ryan TD, van der Pal HJ, van Dalen EC, Kremer LCM (2018) J Clin Oncol 36(21): 2135-2144
    › Primary publication · 29874141 (PubMed)
  18. Myocarditis Associated with Immune Checkpoint Inhibitors: An Expert Consensus on Data Gaps and a Call to Action. Neilan TG, Rothenberg ML, Amiri-Kordestani L, Sullivan RJ, Steingart RM, Gregory W, Hariharan S, Hammad TA, Lindenfeld J, Murphy MJ, Moslehi JJ, Checkpoint Inhibitor Safety Working Group (2018) Oncologist 23(8): 874-878
    › Primary publication · 29802220 (PubMed) · PMC6156187 (PubMed Central)
  19. Increased long QT and torsade de pointes reporting on tamoxifen compared with aromatase inhibitors. Grouthier V, Lebrun-Vignes B, Glazer AM, Touraine P, Funck-Brentano C, Pariente A, Courtillot C, Bachelot A, Roden DM, Moslehi JJ, Salem JE (2018) Heart 104(22): 1859-1863
    › Primary publication · 29720397 (PubMed)
  20. In Silico Pharmacoepidemiologic Evaluation of Drug-Induced Cardiovascular Complications Using Combined Classifiers. Cai C, Fang J, Guo P, Wang Q, Hong H, Moslehi J, Cheng F (2018) J Chem Inf Model 58(5): 943-956
    › Primary publication · 29712429 (PubMed) · PMC5975252 (PubMed Central)
  21. Autochthonous tumors driven by loss have an ongoing requirement for the RBP2 histone demethylase. McBrayer SK, Olenchock BA, DiNatale GJ, Shi DD, Khanal J, Jennings RB, Novak JS, Oser MG, Robbins AK, Modiste R, Bonal D, Moslehi J, Bronson RT, Neuberg D, Nguyen QD, Signoretti S, Losman JA, Kaelin WG (2018) Proc Natl Acad Sci U S A 115(16): E3741-E3748
    › Primary publication · 29610306 (PubMed) · PMC5910822 (PubMed Central)
  22. Myocarditis in Patients Treated With Immune Checkpoint Inhibitors. Mahmood SS, Fradley MG, Cohen JV, Nohria A, Reynolds KL, Heinzerling LM, Sullivan RJ, Damrongwatanasuk R, Chen CL, Gupta D, Kirchberger MC, Awadalla M, Hassan MZO, Moslehi JJ, Shah SP, Ganatra S, Thavendiranathan P, Lawrence DP, Groarke JD, Neilan TG (2018) J Am Coll Cardiol 71(16): 1755-1764
    › Primary publication · 29567210 (PubMed) · PMC6196725 (PubMed Central)
  23. Inhibition of the -Subunit of Phosphoinositide 3-Kinase in Heart Increases Late Sodium Current and Is Arrhythmogenic. Yang T, Meoli DF, Moslehi J, Roden DM (2018) J Pharmacol Exp Ther 365(3): 460-466
    › Primary publication · 29563327 (PubMed) · PMC5931436 (PubMed Central)
  24. Radiation-Induced Cardiovascular Toxicity: Mechanisms, Prevention, and Treatment. Spetz J, Moslehi J, Sarosiek K (2018) Curr Treat Options Cardiovasc Med 20(4): 31
    › Primary publication · 29556748 (PubMed)
  25. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Moslehi JJ, Salem JE, Sosman JA, Lebrun-Vignes B, Johnson DB (2018) Lancet 391(10124): 933
    › Primary publication · 29536852 (PubMed) · PMC6668330 (PubMed Central)
  26. Comorbidities: Cardiovascular disease and breast cancer. Moey M, Moslehi J (2018) Nat Rev Cardiol 15(4): 200-202
    › Primary publication · 29532794 (PubMed)
  27. Cancer therapy-induced cardiomyopathy: can human induced pluripotent stem cell modelling help prevent it? Stack JP, Moslehi J, Sayed N, Wu JC (2019) Eur Heart J 40(22): 1764-1770
    › Primary publication · 29377985 (PubMed) · PMC6554650 (PubMed Central)
  28. The Clinical Presentation, Survival Outcomes, and Management of Patients With Renal Cell Carcinoma and Cardiac Metastasis Without Inferior Vena Cava Involvement: Results From a Pooled Clinical Trial Database and Systematic Review of Reported Cases. Viteri Malone MA, Ares GR, De Velasco G, Brandão R, Lin X, Norton C, Simantov R, Moslehi J, Krajewski KM, Choueiri TK, McKay RR (2018) Clin Genitourin Cancer 16(2): e327-e333
    › Primary publication · 29361425 (PubMed)
  29. Mechanisms of VEGF (Vascular Endothelial Growth Factor) Inhibitor-Associated Hypertension and Vascular Disease. Pandey AK, Singhi EK, Arroyo JP, Ikizler TA, Gould ER, Brown J, Beckman JA, Harrison DG, Moslehi J (2018) Hypertension 71(2): e1-e8
    › Primary publication · 29279311 (PubMed) · PMC5825002 (PubMed Central)
  30. Cardiovascular care of patients with chronic myeloid leukemia (CML) on tyrosine kinase inhibitor (TKI) therapy. Barber MC, Mauro MJ, Moslehi J (2017) Hematology Am Soc Hematol Educ Program 2017(1): 110-114
    › Primary publication · 29222244 (PubMed) · PMC6142546 (PubMed Central)
  31. Smoldering myocarditis following immune checkpoint blockade. Norwood TG, Westbrook BC, Johnson DB, Litovsky SH, Terry NL, McKee SB, Gertler AS, Moslehi JJ, Conry RM (2017) J Immunother Cancer 5(1): 91
    › Primary publication · 29157297 (PubMed) · PMC5697345 (PubMed Central)
  32. Recurrent cardiotoxicity potentiated by the interaction of proteasome inhibitor and immunomodulatory therapy for the treatment of multiple myeloma. Fradley MG, Groarke JD, Laubach J, Alsina M, Lenihan DJ, Cornell RF, Maglio M, Shain KH, Richardson PG, Moslehi J (2018) Br J Haematol 180(2): 271-275
    › Primary publication · 29048105 (PubMed)
  33. Survivorship, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. Denlinger CS, Sanft T, Baker KS, Baxi S, Broderick G, Demark-Wahnefried W, Friedman DL, Goldman M, Hudson M, Khakpour N, King A, Koura D, Kvale E, Lally RM, Langbaum TS, Melisko M, Montoya JG, Mooney K, Moslehi JJ, O'Connor T, Overholser L, Paskett ED, Peppercorn J, Rodriguez MA, Ruddy KJ, Silverman P, Smith S, Syrjala KL, Tevaarwerk A, Urba SG, Wakabayashi MT, Zee P, Freedman-Cass DA, McMillian NR (2017) J Natl Compr Canc Netw 15(9): 1140-1163
    › Primary publication · 28874599 (PubMed) · PMC5865602 (PubMed Central)
  34. Loss of the melanocortin-4 receptor in mice causes dilated cardiomyopathy. Litt MJ, Okoye GD, Lark D, Cakir I, Moore C, Barber MC, Atkinson J, Fessel J, Moslehi J, Cone RD (2017) Elife
    › Primary publication · 28829041 (PubMed) · PMC5577919 (PubMed Central)
  35. Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials. Brown JR, Moslehi J, O'Brien S, Ghia P, Hillmen P, Cymbalista F, Shanafelt TD, Fraser G, Rule S, Kipps TJ, Coutre S, Dilhuydy MS, Cramer P, Tedeschi A, Jaeger U, Dreyling M, Byrd JC, Howes A, Todd M, Vermeulen J, James DF, Clow F, Styles L, Valentino R, Wildgust M, Mahler M, Burger JA (2017) Haematologica 102(10): 1796-1805
    › Primary publication · 28751558 (PubMed) · PMC5622864 (PubMed Central)
  36. 21st Century Cardio-Oncology: Identifying Cardiac Safety Signals in the Era of Personalized Medicine. Sheng CC, Amiri-Kordestani L, Palmby T, Force T, Hong CC, Wu JC, Croce K, Kim G, Moslehi J (2016) JACC Basic Transl Sci 1(5): 386-398
    › Primary publication · 28713868 (PubMed) · PMC5508213 (PubMed Central)
  37. Grounding Cardio-Oncology in Basic and Clinical Science. Moslehi J, Amgalan D, Kitsis RN (2017) Circulation 136(1): 3-5
    › Primary publication · 28674089 (PubMed) · PMC5535811 (PubMed Central)
  38. A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma. Laubach JP, Moslehi JJ, Francis SA, San Miguel JF, Sonneveld P, Orlowski RZ, Moreau P, Rosiñol L, Faber EA, Voorhees P, Mateos MV, Marquez L, Feng H, Desai A, van de Velde H, Elliott J, Shi H, Dow E, Jobanputra N, Esseltine DL, Niculescu L, Anderson KC, Lonial S, Richardson PG (2017) Br J Haematol 178(4): 547-560
    › Primary publication · 28466536 (PubMed)
  39. Cardio-Oncology: Vascular Endothelial Growth Factor Inhibitors, Salt, and Macrophages: A Complicated Interaction. Moslehi J, Pandey AK, Bhatia N (2017) Hypertension 69(5): 785-786
    › Primary publication · 28320853 (PubMed)
  40. Beyond Anthracyclines: Preemptive Management of Cardiovascular Toxicity in the Era of Targeted Agents for Hematologic Malignancies. Sethi TK, Basdag B, Bhatia N, Moslehi J, Reddy NM (2017) Curr Hematol Malig Rep 12(3): 257-267
    › Primary publication · 28233150 (PubMed)
  41. Ventricular arrhythmias and sudden death in patients taking ibrutinib. Lampson BL, Yu L, Glynn RJ, Barrientos JC, Jacobsen ED, Banerji V, Jones JA, Walewska R, Savage KJ, Michaud GF, Moslehi JJ, Brown JR (2017) Blood 129(18): 2581-2584
    › Primary publication · 28223277 (PubMed)
  42. Cardiovascular Toxicities Associated with Cancer Immunotherapies. Wang DY, Okoye GD, Neilan TG, Johnson DB, Moslehi JJ (2017) Curr Cardiol Rep 19(3): 21
    › Primary publication · 28220466 (PubMed)
  43. High-throughput screening of tyrosine kinase inhibitor cardiotoxicity with human induced pluripotent stem cells. Sharma A, Burridge PW, McKeithan WL, Serrano R, Shukla P, Sayed N, Churko JM, Kitani T, Wu H, Holmström A, Matsa E, Zhang Y, Kumar A, Fan AC, Del Álamo JC, Wu SM, Moslehi JJ, Mercola M, Wu JC (2017) Sci Transl Med 9(377)
    › Primary publication · 28202772 (PubMed) · PMC5409837 (PubMed Central)
  44. Myocarditis with Immune Checkpoint Blockade. Moslehi JJ, Johnson DB, Sosman JA (2017) N Engl J Med 376(3): 292
    › Primary publication · 28099832 (PubMed)
  45. Developmental Regulation of Mitochondrial Apoptosis by c-Myc Governs Age- and Tissue-Specific Sensitivity to Cancer Therapeutics. Sarosiek KA, Fraser C, Muthalagu N, Bhola PD, Chang W, McBrayer SK, Cantlon A, Fisch S, Golomb-Mello G, Ryan JA, Deng J, Jian B, Corbett C, Goldenberg M, Madsen JR, Liao R, Walsh D, Sedivy J, Murphy DJ, Carrasco DR, Robinson S, Moslehi J, Letai A (2017) Cancer Cell 31(1): 142-156
    › Primary publication · 28017613 (PubMed) · PMC5363285 (PubMed Central)
  46. Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline. Armenian SH, Lacchetti C, Barac A, Carver J, Constine LS, Denduluri N, Dent S, Douglas PS, Durand JB, Ewer M, Fabian C, Hudson M, Jessup M, Jones LW, Ky B, Mayer EL, Moslehi J, Oeffinger K, Ray K, Ruddy K, Lenihan D (2017) J Clin Oncol 35(8): 893-911
    › Primary publication · 27918725 (PubMed)
  47. Fulminant Myocarditis with Combination Immune Checkpoint Blockade. Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y, Hicks M, Puzanov I, Alexander MR, Bloomer TL, Becker JR, Slosky DA, Phillips EJ, Pilkinton MA, Craig-Owens L, Kola N, Plautz G, Reshef DS, Deutsch JS, Deering RP, Olenchock BA, Lichtman AH, Roden DM, Seidman CE, Koralnik IJ, Seidman JG, Hoffman RD, Taube JM, Diaz LA, Anders RA, Sosman JA, Moslehi JJ (2016) N Engl J Med 375(18): 1749-1755
    › Primary publication · 27806233 (PubMed) · PMC5247797 (PubMed Central)
  48. Cardiovascular Toxic Effects of Targeted Cancer Therapies. Moslehi JJ (2016) N Engl J Med 375(15): 1457-1467
    › Primary publication · 27732808 (PubMed)
  49. Cardiovascular and Thrombotic Complications of Novel Multiple Myeloma Therapies: A Review. Li W, Garcia D, Cornell RF, Gailani D, Laubach J, Maglio ME, Richardson PG, Moslehi J (2017) JAMA Oncol 3(7): 980-988
    › Primary publication · 27632640 (PubMed)
  50. NCCN Guidelines Insights: Survivorship, Version 1.2016. Denlinger CS, Ligibel JA, Are M, Baker KS, Broderick G, Demark-Wahnefried W, Friedman DL, Goldman M, Jones LW, King A, Ku GH, Kvale E, Langbaum TS, McCabe MS, Melisko M, Montoya JG, Mooney K, Morgan MA, Moslehi JJ, O'Connor T, Overholser L, Paskett ED, Peppercorn J, Rodriguez MA, Ruddy KJ, Sanft T, Silverman P, Smith S, Syrjala KL, Urba SG, Wakabayashi MT, Zee P, McMillian NR, Freedman-Cass DA (2016) J Natl Compr Canc Netw 14(6): 715-24
    › Primary publication · 27283164 (PubMed) · PMC5865597 (PubMed Central)
  51. Evaluating the Utility of Baseline Cardiac Function Screening in Early-Stage Breast Cancer Treatment. Truong SR, Barry WT, Moslehi JJ, Baker EL, Mayer EL, Partridge AH (2016) Oncologist 21(6): 666-70
    › Primary publication · 27107002 (PubMed) · PMC4912366 (PubMed Central)
  52. EGLN1 Inhibition and Rerouting of α-Ketoglutarate Suffice for Remote Ischemic Protection. Olenchock BA, Moslehi J, Baik AH, Davidson SM, Williams J, Gibson WJ, Chakraborty AA, Pierce KA, Miller CM, Hanse EA, Kelekar A, Sullivan LB, Wagers AJ, Clish CB, Vander Heiden MG, Kaelin WG (2016) Cell 165(2): 497
    › Primary publication · 27058668 (PubMed)
  53. Cardio-Oncology Training: A Proposal From the International Cardioncology Society and Canadian Cardiac Oncology Network for a New Multidisciplinary Specialty. Lenihan DJ, Hartlage G, DeCara J, Blaes A, Finet JE, Lyon AR, Cornell RF, Moslehi J, Oliveira GH, Murtagh G, Fisch M, Zeevi G, Iakobishvili Z, Witteles R, Patel A, Harrison E, Fradley M, Curigliano G, Lenneman CG, Magalhaes A, Krone R, Porter C, Parasher S, Dent S, Douglas P, Carver J (2016) J Card Fail 22(6): 465-71
    › Primary publication · 27038642 (PubMed)
  54. Cardiovascular Complications of Novel Multiple Myeloma Treatments. Li W, Cornell RF, Lenihan D, Slosky D, Jagasia M, Piazza G, Moslehi J (2016) Circulation 133(9): 908-12
    › Primary publication · 26927008 (PubMed)
  55. EGLN1 Inhibition and Rerouting of α-Ketoglutarate Suffice for Remote Ischemic Protection. Olenchock BA, Moslehi J, Baik AH, Davidson SM, Williams J, Gibson WJ, Chakraborty AA, Pierce KA, Miller CM, Hanse EA, Kelekar A, Sullivan LB, Wagers AJ, Clish CB, Vander Heiden MG, Kaelin WG (2016) Cell 164(5): 884-95
    › Primary publication · 26919427 (PubMed) · PMC4819986 (PubMed Central)
  56. Cardiovascular Effects of Androgen Deprivation Therapy for the Treatment of Prostate Cancer: ABCDE Steps to Reduce Cardiovascular Disease in Patients With Prostate Cancer. Bhatia N, Santos M, Jones LW, Beckman JA, Penson DF, Morgans AK, Moslehi J (2016) Circulation 133(5): 537-41
    › Primary publication · 26831435 (PubMed) · PMC5029929 (PubMed Central)
  57. Cardio-Oncology: How New Targeted Cancer Therapies and Precision Medicine Can Inform Cardiovascular Discovery. Bellinger AM, Arteaga CL, Force T, Humphreys BD, Demetri GD, Druker BJ, Moslehi JJ (2015) Circulation 132(23): 2248-58
    › Primary publication · 26644247 (PubMed) · PMC4863699 (PubMed Central)
  58. Cardiovascular disease following hematopoietic stem cell transplantation: Pathogenesis, detection, and the cardioprotective role of aerobic training. Scott JM, Armenian S, Giralt S, Moslehi J, Wang T, Jones LW (2016) Crit Rev Oncol Hematol : 222-34
    › Primary publication · 26643524 (PubMed) · PMC5003053 (PubMed Central)
  59. Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer. Dang C, Guo H, Najita J, Yardley D, Marcom K, Albain K, Rugo H, Miller K, Ellis M, Shapira I, Wolff AC, Carey LA, Moy B, Groarke J, Moslehi J, Krop I, Burstein HJ, Hudis C, Winer EP, Tolaney SM (2016) JAMA Oncol 2(1): 29-36
    › Primary publication · 26539793 (PubMed) · PMC5654518 (PubMed Central)
  60. Cardiology Patient Page. ABCDE Steps for Heart and Vascular Wellness Following a Prostate Cancer Diagnosis. Guan J, Khambhati J, Jones LW, Morgans A, Allaf M, Penson DF, Moslehi J (2015) Circulation 132(18): e218-20
    › Primary publication · 26527696 (PubMed) · PMC5004633 (PubMed Central)
  61. Tyrosine Kinase Inhibitor-Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia. Moslehi JJ, Deininger M (2015) J Clin Oncol 33(35): 4210-8
    › Primary publication · 26371140 (PubMed) · PMC4658454 (PubMed Central)
  62. Vascular and Metabolic Implications of Novel Targeted Cancer Therapies: Focus on Kinase Inhibitors. Li W, Croce K, Steensma DP, McDermott DF, Ben-Yehuda O, Moslehi J (2015) J Am Coll Cardiol 66(10): 1160-78
    › Primary publication · 26337996 (PubMed)
  63. QT Prolongation and Oncology Drug Development. Fradley MG, Moslehi J (2015) Card Electrophysiol Clin 7(2): 341-55
    › Primary publication · 26002398 (PubMed)
  64. Abnormal exercise response in long-term survivors of hodgkin lymphoma treated with thoracic irradiation: evidence of cardiac autonomic dysfunction and impact on outcomes. Groarke JD, Tanguturi VK, Hainer J, Klein J, Moslehi JJ, Ng A, Forman DE, Di Carli MF, Nohria A (2015) J Am Coll Cardiol 65(6): 573-83
    › Primary publication · 25677317 (PubMed)
  65. ABCDE steps to prevent heart disease in breast cancer survivors. Montazeri K, Unitt C, Foody JM, Harris JR, Partridge AH, Moslehi J (2014) Circulation 130(18): e157-9
    › Primary publication · 25462826 (PubMed)
  66. Unravelling the causes of reduced peak oxygen consumption in patients with cancer: complex, timely, and necessary. Koelwyn GJ, Jones LW, Moslehi J (2014) J Am Coll Cardiol 64(13): 1320-2
    › Primary publication · 25257632 (PubMed)
  67. Recognizing and managing left ventricular dysfunction associated with therapeutic inhibition of the vascular endothelial growth factor signaling pathway. Groarke JD, Choueiri TK, Slosky D, Cheng S, Moslehi J (2014) Curr Treat Options Cardiovasc Med 16(9): 335
    › Primary publication · 25099086 (PubMed)
  68. The challenge of cross-trial comparisons using limited data. Laubach JP, Faber EA, Voorhees P, Moslehi J, Varga C, Niculescu L, Anderson KC, Richardson PG (2014) Haematologica 99(8): e145-6
    › Primary publication · 25082787 (PubMed) · PMC4116848 (PubMed Central)
  69. Prolyl hydroxylation by EglN2 destabilizes FOXO3a by blocking its interaction with the USP9x deubiquitinase. Zheng X, Zhai B, Koivunen P, Shin SJ, Lu G, Liu J, Geisen C, Chakraborty AA, Moslehi JJ, Smalley DM, Wei X, Chen X, Chen Z, Beres JM, Zhang J, Tsao JL, Brenner MC, Zhang Y, Fan C, DePinho RA, Paik J, Gygi SP, Kaelin WG, Zhang Q (2014) Genes Dev 28(13): 1429-44
    › Primary publication · 24990963 (PubMed) · PMC4083087 (PubMed Central)
  70. Cardiology patient page. Breast cancer chemotherapy and your heart. Unitt C, Montazeri K, Tolaney S, Moslehi J (2014) Circulation 129(25): e680-2
    › Primary publication · 24958758 (PubMed)
  71. D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice. Akbay EA, Moslehi J, Christensen CL, Saha S, Tchaicha JH, Ramkissoon SH, Stewart KM, Carretero J, Kikuchi E, Zhang H, Cohoon TJ, Murray S, Liu W, Uno K, Fisch S, Jones K, Gurumurthy S, Gliser C, Choe S, Keenan M, Son J, Stanley I, Losman JA, Padera R, Bronson RT, Asara JM, Abdel-Wahab O, Amrein PC, Fathi AT, Danial NN, Kimmelman AC, Kung AL, Ligon KL, Yen KE, Kaelin WG, Bardeesy N, Wong KK (2014) Genes Dev 28(5): 479-90
    › Primary publication · 24589777 (PubMed) · PMC3950345 (PubMed Central)
  72. Heart failure and breast cancer therapies: moving towards personalized risk assessment. Francis SA, Cheng S, Arteaga CL, Moslehi J (2014) J Am Heart Assoc 3(1): e000780
    › Primary publication · 24584746 (PubMed) · PMC3959702 (PubMed Central)
  73. Declining NAD(+) induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging. Gomes AP, Price NL, Ling AJ, Moslehi JJ, Montgomery MK, Rajman L, White JP, Teodoro JS, Wrann CD, Hubbard BP, Mercken EM, Palmeira CM, de Cabo R, Rolo AP, Turner N, Bell EL, Sinclair DA (2013) Cell 155(7): 1624-38
    › Primary publication · 24360282 (PubMed) · PMC4076149 (PubMed Central)
  74. Cancer-drug discovery and cardiovascular surveillance. Groarke JD, Cheng S, Moslehi J (2013) N Engl J Med 369(19): 1779-81
    › Primary publication · 24180496 (PubMed)
  75. Cancer cachexia: getting to the heart of the matter. Groarke JD, Cheng S, Jones LW, Moslehi J (2013) Eur Heart J
    › Primary publication · 24126874 (PubMed)
  76. A Pkd1-Fbn1 genetic interaction implicates TGF-β signaling in the pathogenesis of vascular complications in autosomal dominant polycystic kidney disease. Liu D, Wang CJ, Judge DP, Halushka MK, Ni J, Habashi JP, Moslehi J, Bedja D, Gabrielson KL, Xu H, Qian F, Huso D, Dietz HC, Germino GG, Watnick T (2014) J Am Soc Nephrol 25(1): 81-91
    › Primary publication · 24071006 (PubMed) · PMC3871766 (PubMed Central)
  77. MicroRNA-26a regulates pathological and physiological angiogenesis by targeting BMP/SMAD1 signaling. Icli B, Wara AK, Moslehi J, Sun X, Plovie E, Cahill M, Marchini JF, Schissler A, Padera RF, Shi J, Cheng HW, Raghuram S, Arany Z, Liao R, Croce K, MacRae C, Feinberg MW (2013) Circ Res 113(11): 1231-41
    › Primary publication · 24047927 (PubMed) · PMC4068743 (PubMed Central)
  78. Emerging paradigms in cardiomyopathies associated with cancer therapies. Ky B, Vejpongsa P, Yeh ET, Force T, Moslehi JJ (2013) Circ Res 113(6): 754-64
    › Primary publication · 23989717 (PubMed) · PMC4046703 (PubMed Central)
  79. Cardio-oncology: it takes two to translate. Moslehi J, Cheng S (2013) Sci Transl Med 5(187): 187fs20
    › Primary publication · 23720578 (PubMed)
  80. Cardiovascular complications of radiation therapy for thoracic malignancies: the role for non-invasive imaging for detection of cardiovascular disease. Groarke JD, Nguyen PL, Nohria A, Ferrari R, Cheng S, Moslehi J (2014) Eur Heart J 35(10): 612-23
    › Primary publication · 23666251 (PubMed) · PMC3945797 (PubMed Central)
  81. The cardiovascular perils of cancer survivorship. Moslehi J (2013) N Engl J Med 368(11): 1055-6
    › Primary publication · 23484833 (PubMed)
  82. Cardiovascular complications associated with novel angiogenesis inhibitors: emerging evidence and evolving perspectives. Bair SM, Choueiri TK, Moslehi J (2013) Trends Cardiovasc Med 23(4): 104-13
    › Primary publication · 23290365 (PubMed) · PMC3621011 (PubMed Central)
  83. Myocardial extracellular volume by cardiac magnetic resonance imaging in patients treated with anthracycline-based chemotherapy. Neilan TG, Coelho-Filho OR, Shah RV, Feng JH, Pena-Herrera D, Mandry D, Pierre-Mongeon F, Heydari B, Francis SA, Moslehi J, Kwong RY, Jerosch-Herold M (2013) Am J Cardiol 111(5): 717-22
    › Primary publication · 23228924 (PubMed) · PMC3578020 (PubMed Central)
  84. Breast cancer therapies and cardiomyopathy. Groarke J, Tong D, Khambhati J, Cheng S, Moslehi J (2012) Med Clin North Am 96(5): 1001-19
    › Primary publication · 22980061 (PubMed)
  85. Left ventricular mass in patients with a cardiomyopathy after treatment with anthracyclines. Neilan TG, Coelho-Filho OR, Pena-Herrera D, Shah RV, Jerosch-Herold M, Francis SA, Moslehi J, Kwong RY (2012) Am J Cardiol 110(11): 1679-86
    › Primary publication · 22917553 (PubMed) · PMC3496816 (PubMed Central)
  86. Management of antiangiogenic therapy-induced hypertension. de Jesus-Gonzalez N, Robinson E, Moslehi J, Humphreys BD (2012) Hypertension 60(3): 607-15
    › Primary publication · 22851729 (PubMed) · PMC3421063 (PubMed Central)
  87. Treatment of erythropoietin deficiency in mice with systemically administered siRNA. Querbes W, Bogorad RL, Moslehi J, Wong J, Chan AY, Bulgakova E, Kuchimanchi S, Akinc A, Fitzgerald K, Koteliansky V, Kaelin WG (2012) Blood 120(9): 1916-22
    › Primary publication · 22611156 (PubMed) · PMC3433093 (PubMed Central)
  88. Telomeres and mitochondria in the aging heart. Moslehi J, DePinho RA, Sahin E (2012) Circ Res 110(9): 1226-37
    › Primary publication · 22539756 (PubMed) · PMC3718635 (PubMed Central)
  89. You can't run from inflammation: lower extremity ischemia, hypoxia signaling, and macrophage subtypes. Moslehi J, Libby P (2012) Circ Res 110(8): 1045-6
    › Primary publication · 22499897 (PubMed)
  90. Reversible cardiomyopathy associated with sunitinib and sorafenib. Uraizee I, Cheng S, Moslehi J (2011) N Engl J Med 365(17): 1649-50
    › Primary publication · 22030001 (PubMed)
  91. Effects of novel angiogenesis inhibitors for the treatment of cancer on the cardiovascular system: focus on hypertension. Nazer B, Humphreys BD, Moslehi J (2011) Circulation 124(15): 1687-91
    › Primary publication · 21986775 (PubMed)
  92. Incidence and risk of congestive heart failure in patients with renal and nonrenal cell carcinoma treated with sunitinib. Richards CJ, Je Y, Schutz FA, Heng DY, Dallabrida SM, Moslehi JJ, Choueiri TK (2011) J Clin Oncol 29(25): 3450-6
    › Primary publication · 21810682 (PubMed)
  93. Telomere dysfunction induces metabolic and mitochondrial compromise. Sahin E, Colla S, Liesa M, Moslehi J, Müller FL, Guo M, Cooper M, Kotton D, Fabian AJ, Walkey C, Maser RS, Tonon G, Foerster F, Xiong R, Wang YA, Shukla SA, Jaskelioff M, Martin ES, Heffernan TP, Protopopov A, Ivanova E, Mahoney JE, Kost-Alimova M, Perry SR, Bronson R, Liao R, Mulligan R, Shirihai OS, Chin L, DePinho RA (2011) Nature 470(7334): 359-65
    › Primary publication · 21307849 (PubMed) · PMC3741661 (PubMed Central)
  94. Loss of hypoxia-inducible factor prolyl hydroxylase activity in cardiomyocytes phenocopies ischemic cardiomyopathy. Moslehi J, Minamishima YA, Shi J, Neuberg D, Charytan DM, Padera RF, Signoretti S, Liao R, Kaelin WG (2010) Circulation 122(10): 1004-16
    › Primary publication · 20733101 (PubMed) · PMC2971656 (PubMed Central)
  95. A feedback loop involving the Phd3 prolyl hydroxylase tunes the mammalian hypoxic response in vivo. Minamishima YA, Moslehi J, Padera RF, Bronson RT, Liao R, Kaelin WG (2009) Mol Cell Biol 29(21): 5729-41
    › Primary publication · 19720742 (PubMed) · PMC2772748 (PubMed Central)
  96. Paragangliomas: etiology, presentation, and management. Joynt KE, Moslehi JJ, Baughman KL (2009) Cardiol Rev 17(4): 159-64
    › Primary publication · 19525677 (PubMed)
  97. Hepatocellular carcinoma with intracavitary cardiac involvement: a case report and review of the literature. Sung AD, Cheng S, Moslehi J, Scully EP, Prior JM, Loscalzo J (2008) Am J Cardiol 102(5): 643-5
    › Primary publication · 18721529 (PubMed)
  98. Somatic inactivation of the PHD2 prolyl hydroxylase causes polycythemia and congestive heart failure. Minamishima YA, Moslehi J, Bardeesy N, Cullen D, Bronson RT, Kaelin WG (2008) Blood 111(6): 3236-44
    › Primary publication · 18096761 (PubMed) · PMC2265460 (PubMed Central)
  99. cGMP catabolism by phosphodiesterase 5A regulates cardiac adrenergic stimulation by NOS3-dependent mechanism. Takimoto E, Champion HC, Belardi D, Moslehi J, Mongillo M, Mergia E, Montrose DC, Isoda T, Aufiero K, Zaccolo M, Dostmann WR, Smith CJ, Kass DA (2005) Circ Res 96(1): 100-9
    › Primary publication · 15576651 (PubMed)
  100. Diverse effects of mutations in exon II of the von Hippel-Lindau (VHL) tumor suppressor gene on the interaction of pVHL with the cytosolic chaperonin and pVHL-dependent ubiquitin ligase activity. Hansen WJ, Ohh M, Moslehi J, Kondo K, Kaelin WG, Welch WJ (2002) Mol Cell Biol 22(6): 1947-60
    › Primary publication · 11865071 (PubMed) · PMC135590 (PubMed Central)
  101. An intact NEDD8 pathway is required for Cullin-dependent ubiquitylation in mammalian cells. Ohh M, Kim WY, Moslehi JJ, Chen Y, Chau V, Read MA, Kaelin WG (2002) EMBO Rep 3(2): 177-82
    › Primary publication · 11818338 (PubMed) · PMC1083969 (PubMed Central)
  102. Posterior urethral valves presented at birth despite normal prenatal ultrasound scans. Moslehi J, Herndon CD, McKenna PH (2001) Urology 57(6): 1178
    › Primary publication · 11377342 (PubMed)
  103. Perforin protects against autoimmunity in lupus-prone mice. Peng SL, Moslehi J, Robert ME, Craft J (1998) J Immunol 160(2): 652-60
    › Primary publication · 9551899 (PubMed)
  104. Influence of antigen organization on the development of lupus autoantibodies. Fatenejad S, Bennett M, Moslehi J, Craft J (1998) Arthritis Rheum 41(4): 603-12
    › Primary publication · 9550469 (PubMed)
  105. Roles of interferon-gamma and interleukin-4 in murine lupus. Peng SL, Moslehi J, Craft J (1997) J Clin Invest 99(8): 1936-46
    › Primary publication · 9109438 (PubMed) · PMC508018 (PubMed Central)